Crossover

DEVICE4 trials

Sponsors

Suzuki Atsushi, NeoTract, Inc., Ospedale Generale Di Zona Moriggia-Pelascini, Vertex Pharmaceuticals

Conditions

Benign Prostatic HyperplasiaMucoviscidosisNeuropathic pain (diabetic neuropathy, traumatic neuropathy, post-infection neuropathy) Neuropathic painParkinson's Disease

Phase 2

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR Mutation

Active, not recruitingNL-OMON46161

Vertex PharmaceuticalsMucoviscidosis

Start: 2017-01-31Target: 20Updated: 2024-02-28

Phase 3

A crossover study of a novel dosage form of mirogabalin for the treatment of peripheral neuropathic pain

Active, not recruitingJPRN-jRCTs041210001

Suzuki AtsushiNeuropathic pain (diabetic neuropathy, traumatic neuropathy, post-infection neuropathy) Neuropathic pain

Start: 2021-04-01Target: 30Updated: 2025-07-18

Unknown Phase

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

CompletedNCT01294150

NeoTract, Inc.Benign Prostatic Hyperplasia

Start: 2011-02-28End: 2017-07-05Updated: 2018-09-05

Crossover Versus Stabilometric Platform in Parkinson's Disease

CompletedNCT02098577

Ospedale Generale Di Zona Moriggia-PelasciniParkinson's Disease

Start: 2013-06-30End: 2014-02-28Updated: 2014-03-28

Related Papers

Effectiveness of convective water vapor energy therapy versus prostatic urethral lift for symptomatic benign prostatic hyperplasia: a systematic review and indirect comparison.

2021-01-306 citations

MP45-12 CONVECTIVE WATER VAPOR ENERGY THERAPY (WAVE) VERSUS PROSTATIC URETHRAL LIFT (PUL) FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH): AN INDIRECT COMPARISON ANCHORED ON SHAM CONTROL.

The Journal of Urology2019-04-01